Phase 2 Lung Cancer Trial, Not Yet Recruiting
voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice
Who may and may not be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who may be able to join
- People with a confirmed diagnosis of non-small cell lung cancer (a common type of lung cancer), at Stage II to IIIB (with specific lymph node involvement), who have not yet received any treatment for it — and where the tumour is classified as advanced based on its size only, not because it has grown into nearby structures like the diaphragm.
- A specialist team review, including a chest surgeon, has confirmed that the tumour can be removed by surgery.
- People who are able to provide a tumour tissue sample for laboratory testing (such as protein and gene analysis).
- People who have at least one tumour that can be measured on a scan, according to standard medical criteria.
- People who are in good general health and able to carry out daily activities, with little to no physical limitations (confirm with trial site what this assessment involves).
Who may not be able to join
Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.
- People whose lung cancer has specific gene changes known as EGFR or ALK mutations (confirm with trial site if unsure whether testing has been done).
- People who have had another type of cancer within the past 5 years — though some exceptions may apply, such as certain treated skin cancers, early-stage cervical cancer, or certain prostate or breast cancers treated with surgery (confirm with trial site for details).
- People who have previously received certain types of cancer immunotherapy treatments, including immune checkpoint inhibitors or similar immune-targeting drugs.
- People who have taken immune-suppressing medications or high-dose steroid tablets (above a certain daily dose) within the two weeks before joining the trial.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: 13719229662
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Pathologic Complete Response (pCR) Rate
Can't join this trial?
Data last synced from ClinicalTrials.gov: 17 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.